Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Revenues of $92.4 billion grew by 14% over the prior year, with double-digit growth again at both Optum and UnitedHealthcare |
| The third quarter results we reported today reflect well-balanced and durable growth, supported by disciplined execution, and a steadfast commitment to ensure high quality comprehensive care is well within reach for every person we're privileged to serve |
| That has really been the story behind the investments of 2023 in response to the changes that have been signaled by CMS, so that we go into ‘24, ‘25, ‘26, ‘27 feeling strong, feeling that we've taken advantage of these last several months to ensure that we've adjusted and adapted our strategy and business in readiness for the change in the funding environment, which gives us strong confidence for next year and underpins our commitment to the signal I just gave you in terms of our potential for 2024 |
| I think our membership looks good in terms of the outlook that we set at the beginning of the year |
| Based on this performance, we're strengthening our 2023 adjusted earnings outlook to a range of $24.85 to $25 per share |
| The confidence we have in our sustained long-term growth outlook is exemplified by the 14% third quarter revenue increase we reported this morning, more than $11 billion above last year |
| The sources of this growth will drive many more years of strong performance |
| This is really translating the type of growth and performance that I think you've come to expect from UnitedHealthCare, and I think it sets up a really nice baseline that I remain optimistic about as we look forward to 2024 |
| Make no mistake, OptumHealth is having a very strong growth year and we're taking the opportunity this year to really ready ourselves and build strength for the next many years of that business |
| And as we look forward, we're very confident about continued strengthening of that business |
| Now, as that speaks to the future, two things really, A.J., one is we're super confident around our ability to continue to grow the number of patients, who are able to look after |
| Our reach rate for the programs that we've implemented exceeds that of our traditional programs, and we're seeing strong re-enrollment rates between 15% and 20% depending on the state |
| As I said back in the last call, we're very, very pleased to have that growth |
| So very strong, and you heard in our opening commentary, very strong growth in the number of fully accountable lives running at about 900,000, substantial fraction of that coming in the more complex cases |
| Medicare Advantage continues to be a powerful force in driving superior health outcomes for consumers and in helping to lower costs at the system level |
| have chosen Medicare Advantage over traditional Medicare, and that number will continue to expand for very good reasons |
| And we're pretty pleased with our ability to hire and manage our operations going forward |
| Importantly, this high value for consumers is delivered at a lower cost to the health system |
| And as we think about that growth, of course, UnitedHealthcare is a core partner to us, but we continue to have the strength of our medical groups and physician networks being incredibly attractive to other payers regionally and nationally to be able to grow in their own value-based arrangements to drive outcomes and total cost of care |
| Looking to the 2024 enrollment period, which begins Sunday, we're confident our offerings will again resonate with consumers as they prioritize high-quality care and stable benefits |
| I want to highlight one more aspect of our growth story, the consistently strong performance of our pharmacy businesses |
| We've had great growth in fully accountable membership as we mentioned earlier, adding over 900,000 patients for the year |
| You know, we're very positive about the potential for another tool in the toolbox to help folks manage their weight |
| First, your MLR was better than our expectations, but curious how it compared to your internal estimates? And maybe you could share how that might have come across -- come in across the three main business segments? And then quickly, on the third quarter UHC margins, I found it interesting that while the MLR deteriorated by 50 basis points year-over-year in the quarter, overall UHC margins actually improved by 50 basis points |
| And as the coming season for 2025 develops, we're expecting another year of robust growth |
| Importantly, the growth we're realizing today and our expanding capacity serve to further reinforce the confidence we have in our long-term 13% to 16% growth objective |
| We continue to expand the reach of our community pharmacies and our diverse specialty and infusion offerings are growing double-digits |
| We're very positive about that, because it's a signal that people are engaging in seeking help for their behavioral conditions |
| Our businesses continue to build momentum, while maintaining flexibility and adaptability for an ever-changing landscape, even as we invest for the future |
| These pillars of our growth, value-based care, pharmacy, and our innovative benefits businesses, alongside our health technology and financial service capabilities, underpin our ability to develop ever stronger value propositions for the people, who receive and those who pay for care and support our confidence in a future of growth |
| Statement |
|---|
| We recognize that has potential benefits, but we're struggling and frankly our clients are struggling with the list prices, which have been demanded of these products in the U.S., which are running at about 10 times the level of price which have been paid in Western Europe |
| And what we're hearing from our clients is they just -- they are really struggling to see how they embark on that journey of what they regard as a kind of open-ended financial risk |
| Obviously, at the health system level, there's a lot of pressures |
| I wanted to ask about OptumHealth, I understand the commentary about membership coming in better, which creates a margin drag, but it feels like a couple of hundred thousand people, maybe low to mid-single-digit, more membership than you expected, causing margins to drop from 8% to 7% or 12%, essentially |
| As Andrew said, our customers, payers, employers, people we serve are concerned about the prices of GLP-1s as set by manufacturers |
| And as you alluded to, Lisa, obesity and cardiometabolic disease is a major public issue -- health issue in the U.S |
| But what I would also say is, you know, we see a little bit of upward pressure on unit costs related to wages, but as I sit here today, it's not something that we haven't planning for and priced about |
| And to no surprise, healthcare costs top their list of concerns, especially the rising cost of drugs |
| As I think about our own business, we haven't had trouble recruiting people such as nurses, clinicians |
| You know, it's similar to last quarter, the trend in margin and OptumHealth and OptumInsight has been down year-to-year, you know, you've called out change, particularly with OptumInsight, but I wondered if there's any ability to discuss unusual items, non-recurring items |
| Driving this expanding market demand is the enormous pressure facing employers, health plans, governments and others to manage and respond to manufacturer list pricing |
| Many of these patients have serious health challenges, few economic resources, and until now often had limited access to care or the type of care they truly need |
| As we look forward, are our customers considering to cover more or less? I would say it's a mixed bag, some are seeking coverage albeit dissatisfied with the price points |
| So first off, what we're seeing, I think, consistent with what states have reported is significant disenrollment for procedural reasons |
| And at this point, I feel all of this is manageable |
| You know, as we sit here today, it's lucky that we sort of have three-year contracts, so it's muted a little bit |
| So we've seen obviously the elevation in MLR which has stabilized, hasn't really come down, isn't accelerating up, but definitely is a phenomena year-over-year, number one, number two, increased behavioral care costs |
Please consider a small donation if you think this website provides you with relevant information